Cancer clinical trials in the region Île-de-France
766 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Brain tumors / Central nervous system tumors
#NCT03932981
#2018-002654-79
Required histologic types
Gliomas
Required histologic sub types
Low-grade glioma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Radiotherapy
2 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 2
Lung cancer
#NCT07680764
#2026-525170-19-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
3 recruiting sites
Bristol-Myers Squibb
Phase 2
Multiple myeloma
#NCT07589634
#2025-524793-42
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Janssen
Phase 2
Breast cancer
Lung cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
#NCT07259226
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Invasive bladder cancer
Upper excretory tract cancer
Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
2 recruiting sites
UNICANCER
Phase 2
Brain tumors / Central nervous system tumors
#NCT03970447
#2024-511452-40-00
GBM récurrent
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
2
Required previous treatments
Chemotherapy
Radiotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
Bevacizumab
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2
Brain tumors / Central nervous system tumors
#NCT03970447
#2024-511452-40-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Immunotherapy
Chemotherapy
Radiotherapy
Radiochemotherapy
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT05128825
Partie partie 2c (Cyclin E1 positive)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2
Lymphoma
#NCT06526793
#2023-505789-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Follicular lymphoma
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Brain tumors / Central nervous system tumors
Skin cancer
#NCT02029001
#2012-004510-34
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ATM
BRCA 1/2
PALB2
Other mutation
Required number of previous lines of therapy
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Centre Léon Bérard
Phase 2
Liver and bile duct cancer
#NCT07219459
#2025-520675-86-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
CatalYm GmbH